The Patent Dance Is Not a DanceIts a Deadline. Heres How Biosimilar Developers Win (or Lose) Before Court Ever Opens.
If youve ever watched a biosimilar case unfold, youve probably noticed the same pattern: the real fight doesnt start in the courtroom….

Drug patent cliffs are no longer a surprisetheyre a forecast.
For years, pharma strategy teams have treated patent expiration like weather: you can track it, but you cant control itand you definitely cant predict it with certainty until its already on …

Patent thickets arent just a legal nuisancetheyre a market strategy. And if youre a biotech, pharma, or generic company trying to launch into a crowded therapeutic space, the real question isnt Can we win? Its Can we sequence our moves so the thicket c…

Blockbuster patents dont just protect moleculesthey protect how the molecule is made.
Thats the uncomfortable truth behind formulation forensics: the idea that if you want to design around a blockbuster drug patent, you cant stop at the active ingred…

Pharma boards dont fear litigation. They fear what litigation does to decisions.
When a patent case lands on the deskespecially one involving a blockbuster or a platform assetthe immediate question is usually legal: Who wins? But the board-level questi…

Designing Around Formulation Patents: The Generic Developers Playbook (and Why Its Getting Harder)
In generic drug development, the fastest path to market is rarely a straight line. Its a mazeone where the walls arent just clinical, manufacturing, or r…

Pharma Forensics: The Quiet Skill That Lets You Decode a Competitors Lifecycle Strategy
In pharma, the loudest signals are rarely the most important.
A press release about pipeline momentum can be trueand still miss the real story. The real story is of…

Designing Around the Moat: How Generic Developers Can Win the Secondary-Patent Game
In generic drug development, the first patent is rarely the whole story.
Yes, the primary patent often grabs headlinesexpiration dates, Paragraph IV challenges, and the…

Patent cliffs arent just a legal eventtheyre a supply-chain stress test.
If youre responsible for procurement, planning, manufacturing, or commercial operations, the next wave of blockbuster expirations will hit like weather: predictable in theory, d…

Most patent searches miss the real fight.
If youve ever run a keyword-only prior art search, you already know the uncomfortable truth: youre not finding what mattersyoure finding what you can name.
In pharma and biotech, that gap can be the differenc…